- Baker Brothers’ 13F portfolio value increased from $16.24B to $22.67B this quarter.
- Stakes in InVitae and MyoKardia were increased substantially while reducing Neurocrine Biosciences and Principia Biopharma.
- The top three positions are Seattle Genetics, Incyte Corporation, and BeiGene Ltd. and they add up to almost ~61% of the portfolio.
This article is part of a series that provides an ongoing
analysis of the changes made to Baker Brothers’ 13F portfolio on a quarterly
basis. It is based on Baker Brothers’ regulatory 13F Form filed on 08/14/2020.
This quarter, Baker Brothers’ 13F portfolio value increased
~40% from ~$16.24B to $22.67B. The top three holdings are at ~60% while the top
five holdings are at ~73% of the 13F assets: Seattle Genetics (SGEN), Incyte
Corporation (INCY), BeiGene (BGNE), Acadia Pharma (ACAD), and Alexion
Pharmaceuticals (ALXN).
The spreadsheet below highlights changes to Baker Brothers’
13F holdings in Q2 2020. For a look at how the portfolio has progressed, please
see our previous
update:
To learn more about how to profit from a strategy of
following the best hedge fund picks, check out our book Profiting from Hedge Funds: Winning Strategies for the Little
Guy .
No comments :
Post a Comment